eCite Digital Repository

Patients with rheumatoid arthritis in the Australian OPAL cohort show significant improvement in disease activity over 5 years: a multicenter observational study

Citation

Littlejohn, G and Roberts, L and Bird, P and de Jager, J and Griffiths, H and Nicholls, D and Young, J and Zochling, J and Tymms, KE, Patients with rheumatoid arthritis in the Australian OPAL cohort show significant improvement in disease activity over 5 years: a multicenter observational study, Journal of Rheumatology, 42, (9) pp. 1603-1609. ISSN 0315-162X (2015) [Refereed Article]

Copyright Statement

The Journal of Rheumatology 2015. All rights reserved.

DOI: doi:10.3899/jrheum.141575

Abstract

Objective: To evaluate disease activity trends in a large cohort of Australian patients with rheumatoid arthritis (RA) from 2009 to 2014.

Methods: This is a multicenter, cross-sectional, noninterventional study of patients with RA treated in Australia. Patients with RA treated at participating OPAL (Optimising Patient outcome in Australian RheumatoLogy) clinics were included in the study. Data, deidentified by patient, clinic, and clinician, were identified using a purpose-written electronic medical record. Patient demographics, disease onset, medications, and disease measures were analyzed. The Disease Activity Score at 28 joints (DAS28) was used to classify patients into the disease activity states of remission: low disease activity, moderate disease activity (MDA), and high disease activity. Choice of therapy was at the discretion of the treating clinician.

Results: At the time of analysis, the database contained 15,679 patients with RA, 8998 of whom fulfilled the inclusion criteria. Mean age was 63.2 years, mean disease duration was 13.8 years, and the majority were women (72.4%). A total of 37,274 individual DAS28-erythrocyte sedimentation rate scores were recorded for the 8998 patients. The frequency of remission increased significantly from 36.7% in 2009 to 53.5% in 2014 (p<0.001), and that of MDA decreased from 33% (2009) to 22.2% (2014). The use of biologic disease-modifying antirheumatic drugs for the patients in remission increased from 17% in 2009 to 36.9% in 2014.

Conclusion: Contemporary management of RA in Australia shows improvements in disease activity toward the target of remission over a 5-year period.

Item Details

Item Type:Refereed Article
Keywords:rheumatoid arthritis, remission, disease activity, disease-modifying antirheumatic drugs
Research Division:Medical and Health Sciences
Research Group:Clinical Sciences
Research Field:Rheumatology and Arthritis
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Skeletal System and Disorders (incl. Arthritis)
Author:Zochling, J (Dr Jane Zochling)
ID Code:102096
Year Published:2015
Web of Science® Times Cited:2
Deposited By:Menzies Institute for Medical Research
Deposited On:2015-07-28
Last Modified:2017-11-03
Downloads:0

Repository Staff Only: item control page